Capula Management LTD Amgen Inc Transaction History

Capula Management LTD

$9.23 Billion
Q3 2024

A detailed history of Capula Management LTD transactions in Amgen Inc stock. As of the latest transaction made, Capula Management LTD holds 500 shares of AMGN stock, worth $139,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares

500

Previous 101 395.05%

Holding current value

$139,380

Previous $31,000 419.35%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$309.38 - $337.38 $205,428 - $224,020	664 Added 657.43%	765 $246,000
Q2 2024 Aug 05, 2024	BUY	$262.75 - $319.31 $26,537 - $32,250	101 New	101 $31,000
Q4 2023 Feb 12, 2024	BUY	$255.7 - $288.46 $55,486 - $62,595	217 New	217 $62,000
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $218,341 - $258,184	-1,019 Reduced 52.53%	921 $204,000
Q1 2023 May 10, 2023	SELL	$225.79 - $275.2 $13.8 Million - $16.8 Million	-61,153 Reduced 96.93%	1,940 $468,000
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $3.56 Million - $4.52 Million	15,522 Added 32.63%	63,093 $16.6 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $10.7 Million - $12 Million	47,571 New	47,571 $10.7 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $1.45 Million - $1.66 Million	-7,293 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$212.27 - $248.7 $1.52 Million - $1.78 Million	7,164 Added 5553.49%	7,293 $1.55 Million
Q2 2021 Aug 13, 2021	SELL	$233.58 - $259.14 $359,946 - $399,334	-1,541 Reduced 92.28%	129 $31,000
Q1 2021 May 14, 2021	BUY	$221.91 - $258.6 $370,589 - $431,862	1,670 New	1,670 $416,000

Others Institutions Holding AMGN

# of Institutions

3,119

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $149B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Capula Management LTD with notifications on news.

Account

Capula Management LTD Amgen Inc Transaction History